Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) is a biopharmaceutical company that focuses on developing medicines for people with serious diseases, with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and cancer treatments.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Jazz Pharmaceuticals has undertaken a comprehensive range of R&D initiatives that encompass all stages of development, including clinical testing of new product candidates and clinical improvements of existing marketed products. The company is actively engaged in preclinical and early-stage programs for novel therapies, particularly in the area of rare diseases. Jazz Pharmaceuticals is leveraging its internal R&D capabilities and has entered into collaborations with third parties for the development of innovative early-stage product candidates. The company also supports investigator-sponsored trials to generate additional data related to its products and seeks investment opportunities in early- and mid-stage technologies with a focus on validated targets and mechanisms. The R&D unit of Jazz Pharmaceuticals is responsible for managing the company's research and development activities, which include clinical testing, preclinical and early-stage programs, collaborations with third parties, and support for investigator-sponsored trials. The unit plays a crucial role in advancing the company's rare disease strategy and leveraging its strong R&D capabilities. In oncology, the company’s most advanced growth driver is zanidatamab, a HER2-targeted bispecific (biparatopic) antibody licensed from Zymeworks (global rights across the US, Europe, Japan and most territories), which advanced from a Phase 2 BTC program to regulatory success and global expansion (CHMP positive opinion; EC conditional marketing authorization for Ziihera in previously treated HER2-positive BTC; conditional approval in Canada. Jazz Pharmaceuticals is also expanding the Zepzelca (lurbinectedin) franchise in SCLC. Through the acquisition of Chimerix, Jazz added Modeyso (dordaviprone/ONC201). Jazz Pharmaceuticals is extending Epidiolex with a Phase 1b focal-onset seizure study and is building an early epilepsy portfolio including JZP053 (SAN2355), while pursuing additional preclinical collaborations such as PASylation-enabled half-life extension for asparaginase candidates (XLp), KRAS programs including G12D-selective and pan-KRAS molecules (from Redx), ion-channel discovery partnerships (Autifony), and internal oncology formulation/combination work using its CombiPlex platform. In FY2025, the company spent US$782.7 million on its R&D, which as a percentage of revenue, stood at 18.3% and declined 11% YoY. Some of its pipeline drugs in phase III include Zanidatamab + SOC chemo ± tislelizumab (1L) to treat GEA; Zanidatamab + SOC chemo ± PD-1/L-1 (1L) to treat BTC; and Zanidatamab + chemo to treat previously T-DXd-treated mBC. Drugs in phase II trials include Zanidatamab + SOC chemo (1L) to treat BTC, GEA, CRC; and I-SPY 2 Zanidatamab + SOC to treat breast cancer; Zanidatamab + paclitaxel and ramucirumab to treat Advanced GEA. As of December 2025, Jazz Pharmaceuticals had 15 US patents related to Xywav, seven issued US patents related to Xyrem, and 32 issued US patents related to the use of CBD in the treatment of epileptic encephalopathies.